CAJ | 학술논문

目的：观察伊立替康（ CPT?11）联合雷替曲塞二线治疗晚期胃癌的近期疗效和安全性。方法对33例一线化疗方案治疗失败或缓解后再进展的晚期胃癌患者，应用CPT?11联合雷替曲塞进行化疗，具体为：CPT?11，200 mg／m2静滴90 min，d1；雷替曲塞3 mg／m2静滴15 min，d1；3周为1个周期。每2～3个周期按照RECIST 1?1版标准评价客观疗效，采用国立癌症研究所毒性判定标准（ NCI CTC）4?0评价毒性反应，同时随访其生存情况。结果33例均可评价近期疗效和毒副反应，无CR患者，PR 5例，SD 16例，PD 12例；有效率为15?2％，疾病控制率为63?6％，中位无进展生存期为3?3个月。常见毒副反应有贫血、恶心呕吐、白细胞减少、肝功能损害、迟发性腹泻、血小板减少及便秘，主要为1～2级。结论 CPT?11联合雷替曲塞二线治疗晚期胃癌有一定的疗效，毒副作用可耐受。
목적：관찰이립체강（ CPT?11）연합뢰체곡새이선치료만기위암적근기료효화안전성。방법대33례일선화료방안치료실패혹완해후재진전적만기위암환자，응용CPT?11연합뢰체곡새진행화료，구체위：CPT?11，200 mg／m2정적90 min，d1；뢰체곡새3 mg／m2정적15 min，d1；3주위1개주기。매2～3개주기안조RECIST 1?1판표준평개객관료효，채용국립암증연구소독성판정표준（ NCI CTC）4?0평개독성반응，동시수방기생존정황。결과33례균가평개근기료효화독부반응，무CR환자，PR 5례，SD 16례，PD 12례；유효솔위15?2％，질병공제솔위63?6％，중위무진전생존기위3?3개월。상견독부반응유빈혈、악심구토、백세포감소、간공능손해、지발성복사、혈소판감소급편비，주요위1～2급。결론 CPT?11연합뢰체곡새이선치료만기위암유일정적료효，독부작용가내수。
Objective To evaluate the recent efficacy and safety of irinotecan( CPT?11) plus raltitrexed as second?line regi?men for advanced gastric cancer. Methods Thirty?three patients with advanced gastric cancer were treated with CPT?11(200 mg/m2, 90 min, iv, d1) combined with raltitrexed(3 mg/m2, 15 min, iv, d1) regimen as second?line chemotherapy. Three weeks was a cycle. Response to chemotherapy was assessed by RECIST criteria 1?1 and toxicity was evaluated according to National Cancer Institute Com?mon Toxicity Criteria 4?0. The clinical follow?up data from chemotherapy were investigated. Results Thirty?three patients were all evaluable for recent efficacy and safety. There were no CR, 5 patients of PR, 16 patients of SD, and 12 patients of PD with the re?sponse rate of 15?2% and the disease control rate of 63?6%.The median progression?free survival was 3?3 months. The most common adverse reactions were anemia, nausea, vomiting, leucopenia, dysfunction of liver, delayed diarrhea, thrombocytopenia and constipa?tion, mainly in grade 1?2. Conclusion CPT?11 combined with raltitrexed is an effective and well?tolerated chemotherapy regimen as second?line treatment for advanced gastric cancer.